China SXT Pharmaceuticals, Inc. Operating Income Loss

• China SXT Pharmaceuticals, Inc. showed a decrease of -6.6% in Operating Income Loss from 2024 to 2025.
• This data is from China SXT Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 31, 2025.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), China SXT Pharmaceuticals, Inc.'s Operating Income Loss has declined by 267.3%.
• Historical annual values: Fiscal year 2025: -$2.68 million | Fiscal year 2024: -$2.52 million | Fiscal year 2023: -$5.61 million | Fiscal year 2022: -$5.19 million | Fiscal year 2021: -$2.20 million | Fiscal year 2020: -$1.34 million | Fiscal year 2019: $1.77 million | Fiscal year 2018: $1.63 million | Fiscal year 2017: $1.60 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026